Biotech Co.* (Country; Symbol)

Pharma Co. (Country)

Type/Product Area

Terms/Details (Date)

Aclara BioSciences Inc. (ACLA)

GlaxoSmithKline plc (UK)

Agreement for Aclara to provide its eTag Assay System to GSK

GSK will access the technology for use in its biopharmaceutical research and development activities and for multiplexed gene expression profiling studies (7/30)

Acorda Therapeutics Inc.*

Teva Pharmaceutical Industries Ltd. (Israel)

Co-development and promotion deal for anti- convulsive agent valrocemide

Deal also gives Teva first negotiation rights to Acorda's Fampridine-SR, which is in Phase III; valrocemide is in Phase II; financial terms were not disclosed (9/24)

Agenix Ltd. (Australia; ASX: AGX)

Abbott Laboratories

Agreement to license patents that cover enabling technology used in lateral-flow devices, which are used in point-of-care diagnostics

Agenix's subsidiary, AGEN Biomedical Ltd., will use the lateral-flow technology to develop diagnostic products for animal health applications and to detect D-Dimer, a protein marker indicative of clot formation in humans (8/19)

Alnylam Holding Co.*

Merck & Co. Inc.

Collaboration to develop RNAi-based therapeutics and technology

Merck will provide Alnylam with drug tar- gets that it has validated as having a role in disease; Alnylam will develop RNAi compounds against the targets and advance them through preclinical development; Merck will make an up-front payment, annual cash payments and an equity in- vestment (9/9)

Antares Pharma Inc. (OTC BB:ANTR)

Eli Lilly and Co.

Exclusive agreement for development and use of Antares' needle-free drug delivery technology in the fields of diabetes and obesity

Lilly retained an option for application of the technology in one other therapeutic area; Antares will receive an inital payment and could receive milestone payments and royalties; Lilly also has the option to take an equity position in Antares (9/16)

ArQule Inc. (ARQL)

Novartis Institutes for BioMedical Research Inc. (affiliate of Novartis AG; Switzerland)

Chemistry collaboration in which ArQule will apply its integrated chemistry technology platform to generate and optimize small-molecule compounds for Novartis' anti-infective drug discovery program

Financial terms were not disclosed (9/4)

Astex Technology Ltd.* (UK)

Fujisawa Pharmaceutical Co. Ltd. (Japan)

A structural biology research agreement to design and develop drug candidates

The collaboration will focus on solving human cytochrome P450 crystal structures that will be used to optimize Fujisawa's compounds; Astex will apply its X-ray crystallography technologies to obtain crystal structures of cytochrome P450s complexed to Fujisawa's compounds (8/19)

Caprion Pharmaceuticals Inc.* (Canada)

AstraZeneca plc (UK)

Research collaboration to identify biomarkers for pain using Caprion's CellCarta proteomics discovery platform

Caprion will profile the proteomic changes occurring in plasma resulting from the administration of pharmaceutical compounds in relevant preclinical models (8/11)

Dharmacon Inc.*

Abbott Laboratories

Collaboration to develop an siRNA library covering 4,000 genes to identify drug targets for Abbott's therapeutic areas

The resulting library will enable high- throughput functional genomic studies designed to identify and validate drug targets; the agreement covers genes believed to be important in cancer, diabetes, pain management, inflammation and neurological disorders (7/29)

Discovery Partners International Inc. (DPII)

Kyorin Pharmaceutical Co. Ltd. (Japan)

Research collaboration to identify drug candidates for an allergy target

Discovery Partners is responsible for assay development and hit identification; it will receive ongoing research support and milestone payments; Kyorin has worldwide rights to manufacture and market any resulting products (9/2)

Evotec Neurosciences GmbH (Germany; FSE:EVTG)

Takeda Chemical Industries Ltd. (Japan)

Four-year collaboration in the area of Alzheimer's disease

The companies aim to identify and validate targets relating to different aspects of the causes and progression of Alzheimer's disease, with a goal of developing small- molecule therapeutics; Evotec will grant Takeda access to its database of Alzheimer's disease-related targets, and will validate selected target candidates; Takeda will make payments to Evotec of up to |20M covering database access fees, research funding and milestone payments relating to the selection of targets for further drug discovery (8/1)

FASgen Inc.*

P&G Pharmaceuticals Inc.

Agreement for development of FASgen's products that affect fatty-acid metabolism

The deal includes undisclosed up-front payments, milestones and royalties; obesity, diabetes and related disorders are the focus (9/24)

Flamel Technologies SA (France; FLML)

Bristol-Myers Squibb Co.

Agreement giving Bristol- Myers worldwide rights for the future development and manufacturing of Flamel's  recombinant human insulin product, Basulin

The deal provides Flamel with a $20M up- front payment; the company also could receive another $145M in milestone payments (8/27)

Genaissance Pharmaceuticals Inc. (GNSC)

AstraZeneca plc (UK)

Licensing agreement to use information generated from Genaissance's Statin Response Examined by Genetic Haplotype Markers study

AstraZeneca will receive nonexclusive access to the STRENGTH study database for research purposes for a limited period (9/11)

Genomics Collaborative Inc.*

Novartis AG (Switzerland)

Collaboration on large-scale human genetics program to validate drug targets using GCI's database of biological samples

GCI will work with the Novartis Institutes for  BioMedical Research Inc. to access GCI's Glo- bal Repository library on a nonexclusive basis for two years; the deal covers up to four therapeutic areas, starting with Type II diabetes (9/22)

Hemispherx Biopharma Inc. (AMEX:HEB)

Guangdong Medicine Group Corp. (China)

Agreement for Guangdong to organize clinical trials, marketing, sales and distribution for both of Hemispherx's lead compounds, Alferon and Ampligen, in China

Guangdong will conduct clinical trials with Alferon N injection to treat hepatitis C and with Ampligen to treat HIV (9/4)

Immtech Therapeutics Ltd. (Hong Kong; subsidiary of Immtech International Inc.; AMEX:IMM)

Guo Kang Pharmaceutical & Medical Supplies Ltd. (China)

Collaboration to assist Immtech and its clients in gaining access to China's health care market

Guo Kang is collaborating with Immtech to obtain approvals to introduce DB289, Immtech's first oral drug candidate for treatment of infectious diseases, into China (8/14)

ImmunoGen Inc. (IMGN)

Aventis SA (France)

Agreement to jointly develop antibody-based cancer products

ImmunoGen received a commitment for at least $62M from Aventis, including $12M up front and more than $50M in research funding over three years; ImmunoGen could get more in milestone payments, as well as potential royalties; Aventis gains worldwide rights to any products developed from the agreement, as well as three preclinical antibody-based cancer candidates (7/31)

Inflazyme Pharmaceuticals Ltd. (Canada; TSE: IZP)

Spire Corp.

Agreement for Inflazyme to provide its ATHc anti-thrombotic technology for unspecified fields of use in catheters belonging to Spire

Inflazyme received an immediate license fee and could receive further milestone and option payments, together totaling $600,000 over the next three years (7/25)

Ingenuity Systems*

GlaxoSmithKline plc (UK)

GSK licensed part of the Ingenuity Knowledge Base technology

GSK will use the information in its genome-scale computational efforts to better understand biology underlying disease; financial terms were not disclosed (9/22)

IsoTis SA (Switzerland; SWX ISON)

Healthpoint Ltd. (affiliate of DFB Pharmaceuticals Inc.)

Exclusive, worldwide licensing agreement to a wound-healing technology called Allox

Healthpoint will fund specific developmental activities, pay certain milestones and share a percentage of product income (8/18)

LigoCyte Pharmaceuticals Inc.*

Abbott Laboratories

Research collaboration to develop monoclonal antibodies for inflammatory diseases

Financial terms were not disclosed (8/4)

Lipomics Technologies Inc.*

GlaxoSmithKline plc (UK)

Research collaboration and option agreement for drug discovery and diagnostic development

Lipomics will evaluate the effects of drug compounds on metabolism and establish the mechanism of drug response using TrueMass lipid analysis and customized Surveyor and Insight graphical representations of lipid metabolism (7/31)

Lynx Therapeutics Inc. (LYNX)

Pfizer Inc.

Agreement to study gene expression in cell samples

The agreement features the application of Lynx's Massively Parallel Signature Sequencing technology to cell samples from normal and disease-affected patients in an effort to provide information on specific genes involved in disease progression; Lynx will receive payments for the genomics discovery services it performs on the samples provided by Pfizer under the agreement (8/12)

Meditech Pharmaceuticals Inc. (OTC BB:MDCH)

Elan Bio Dynamics and Bio-D-Tec Inc. (a joint venture between Meditech  Pharmaceuticals Inc. and Elan Group plc; Ireland)

Agreement giving Bio-D-Tec the rights to an Elan scanner and Meditech's aflatoxin technologies

Bio-D-Tec is pursuing potential equity, governmental and strategic alliances to market a solution to bioterrorism (8/26)

Neose Technologies Inc. (NTEC)

Sandoz (unit of Novartis AG; Switzerland)

Agreement in which Neose will use its technologies with a therapeutic recombinant protein that is manufactured and supplied by Sandoz

If both parties elect to proceed with further development and commercialization, they would have co-exclusive worldwide rights (8/15)

NexMed Inc. (NEXM)

Undisclosed Japanese pharmaceutical company

Research and development agreement to develop NM 20138, a once-daily patch treatment for bronchial asthma

NexMed received a signing payment and will receive additional payments based on milestones; NexMed also retained rights to manufacture and commercialize the product worldwide except in Japan (8/7)

NicOx SA (France; NICXF)

Merck & Co. Inc.

Agreement to provide nitric oxide-donating compounds for evaluation in a preclinical testing program in an undisclosed therapeutic area

Merck gained the exclusive right for a fixed period of time to license any selected lead compounds identified, and if it exercises its option it would pay NicOx an initial license fee for drug candidates, success-related milestones and royalties on any future sales of resulting drugs; Merck also would be responsible for funding future development and commercialization on a worldwide basis (8/19)

Nucleonics Inc.*

Wyeth

Agreement in which Nucleonics acquired from Wyeth rights to patent applications  centered on RNA interference for a small equity stake

In exchange for the co-exclusive rights, Nucelonics has given Wyeth 5% of the company (8/20)

ParAllele BioScience Inc.*

Hoffmann-La Roche Inc.

Agreement to discover genes and genetic variations around Type II diabetes

Roche will provide clinical samples for ParAllele in which ParAllele will aim to discover genetic variations; Roche is funding the research (9/16)

Paratek Pharmaceuticals Inc.*

Bayer AG (Germany)

Collaboration to further advance BAY 73-6944/ PTK 0796

Paratek will contribute to global development costs, and it will receive up-front and milestone payments, as well as access to development funds; Paratek also could receive co-promotion and profit-sharing rights, as well as royalties; Bayer will develop, manufacture and market injectable preparations of the product (9/15)

Regeneron Inc. (REGN)

Aventis SA (France)

Agreement focused on Regeneron's VEGF Trap product candidate

Aventis will pay Regeneron $125M, of which $45M is an investment in newly issued stock and $80M is an up-front payment; an early clinical milestone achievement would bring $25M more, and other milestone payments would bring up to another $360M; the companies will share global promotion rights and profits equally, with Aventis funding development costs; if the collaboration, which excludes Japan, becomes profitable, Regeneron would pay back half the development costs (9/8)

SciTegic Inc.*

Boehringer Ingelheim Pharmaceuticals Inc.

Licensing agreement for SciTegic's lead product, Pipeline Pilot

Boehringer is initially using Pipeline Pilot to optimize its compound acquisitions (8/13)

Serenex Inc.*

Eli Lilly and Co.

Research agreement for Serenex to use its chemoproteomics technologies within drug discovery programs belonging to Lilly

Lilly will use Serenex's Proteome Mining and Functional Proteome Fractionation technologies to screen compounds against thousands of protein targets from multiple proteomes, simultaneously and in a single step (8/5)

Syn-X Pharma Inc. (Canada; TSE:SYY)

Ortho-Clinical Diagnostics Inc. (unit of Johnson & Johnson)

Agreement for a pivotal trial for the first in vitro diagnostic test for Alzheimer's disease

The agreement provides financial support to Syn-X for the completion of an ongoing trial that might be submitted to the FDA for approval (8/28)

Theratechnologies Inc. (Canada; TSE:TH)

Johnson & Johnson Pharmaceutical Research & Development LLC

Licensing and research agreement for a therapeutic peptide in the field of diabetes

Theratechnologies has received an up-front payment, and is scheduled to receive re- search and regulatory milestones as well as royalties; development and marketing activities will be handled by J&J (9/4)

Vical Inc. (VICL)

Merck & Co. Inc.

Option license agreement for rights to Vical's DNA delivery technology for three cancer targets

In exchange, Merck returned technology rights in certain infectious disease indi- cations to Vical (8/21)

Vion Pharmaceuticals Inc. (VION)

Eli Lilly and Co.

Research services agreement related to the Phase II trials of Vion's cancer agent Triapine in combination with Lilly's cancer agent Gemzar

The agreement relates to the measurement of the expression of several genes in tumor tissue and blood samples from patients participating in Vion's Phase II trials of the combination therapy in non-small-cell lung cancer and pancreatic cancer (9/8)

ViroPharma Inc. (VPHM)

GlaxoSmithKline plc (UK)

Agreement to develop an antiviral compound called maribavir to treat human cytomegalovirus disease

ViroPharma paid GSK $3.5M up front for the right to develop the compound; it also will make milestone and royalty payments in exchange for exclusive worldwide rights, excluding Japan; ViroPharma also has the right to develop maribavir for HIV patients who contract the virus (8/11)

Notes:

^# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange.